InterGen Data Announces New Client: Spectrum Healthcare Solutions

InterGen Data, Inc | October 18, 2021

InterGen Data Announces New Client: Spectrum Healthcare Solutions

InterGen Data, Inc., a leading provider of Life Event Data, analytics, and predictive modeling, has signed Spectrum Health Solutions “Spectrum” as a new client. Spectrum will utilize InterGen Data’s predictive data to analyze and identify when their patients are likely to have Chronic Illnesses occur, what they might be, and how much they are projected to cost. Spectrum will further use InterGen’s data to help them assess new patient populations as they expand their services into new geographies.

 

“We are really excited about this partnership because we will be delivering a first to the marketplace, artificial intelligence-based solution that will help our practitioners educate people on the risk of how critical illnesses and comorbidities can impact their need for our services,” said Spectrum Health Solutions CEO Stan Thomas. “As an in-home care provider, we know that Life Events affect the entire family. No one is ever really prepared, but this data will allow us to help educate our patients,” Thomas further explained.

“By 2030, the CDC estimates that 74 million Baby Boomers will be over the age of 65. This means that there will be a huge uptick in Critical Illness needs and costs. This ‘Silver Tsunami’ is will not only reshape the health care system forever, but it will have tremendous impact on how wealth is managed and de-cumulated.” 

InterGen Data Founder and CEO Robert J. Kirk

 

“Simply put, there aren’t enough nurses, experienced or not, to manage the volume of people who will need any level of medical care,” said Stan Thomas. “No matter how you try to do the math, the US isn’t properly prepared, but with the help of InterGen Data’s predictive modeling, we feel that we will be better able to help those most likely to need additional healthcare,” Thomas further stated.

 

- - - U.S. Care Statistics - - -

  • The American HealthCare Association (ACHA) and the National Center for Assisted Living (NCAL) there are 28,900 assisted living communities with nearly 1 million licensed beds in the US
  • The Kaiser Family Foundation (KFF), a non-profit organization focusing on national health issues, states that there are 15,327 total number of certified nursing facilities that have approximately 1.7 million licensed beds.
  • The American Association of Colleges of Nursing (AACN) states that the U.S. is projected to experience a shortage of Registered Nurses (RN’s) that is expected to intensify as Baby Boomers age and the need for health care grows
  • The Nurse Journal states that data from The Bureau of Labor and Statistics (BLS) depicts Washington, Dallas, Los Angeles, Houston, and New York City have the lowest local concentrations of nurse employment vs. national nurse employment.

 

About InterGen Data, Inc.

InterGen Data, Inc. (InterGen Data) was founded by the financial services industry veteran Robert J. Kirk in December 2017. InterGen Data is an award winning Life Event Data provider that uses the latest in predictive modeling techniques and patent pending proprietary algorithms that identify when someone is likely to have an important life event occur, what that event could be, and how much of a economic impact that it would have on their financial journey. They supply this data to banks, financial services, and insurance companies.

 

About Spectrum Healthcare Solutions

Spectrum Health Solutions was formed in 2017 primarily to service the under served market of patients at home. Its vision is to “Change the face of healthcare at home”. Spectrum primarily services patients from 18 years of age to death. Currently Spectrum services patients in the Texas and Oklahoma market, with plans to expand into Florida, Illinois and California in the near future. It is a health care company that sees patients at home and uses technology to improve the care given and the company’s bottom line.

Spotlight

Full Story: http://bit.ly/1PZ7dMw - An innovative new tool in the fight against breast cancer allows patients to undergo a one-time radiation treatment, directly in the cavity where the tumor has been removed, during surgery for early-stage breast cancer. A team of community and faculty doctors at Emory University Hospital Midtown is now treating patients with Intraoperative Radiation Therapy (IORT) during breast-conserving surgeries.


Other News
HEALTH TECHNOLOGY

The GIANT Health Event 2021. Early bird tickets on sale now

GIANT Health | October 13, 2021

Europe's greatest festival of Health Tech Innovation | 30th Nov - 1st Dec 2021 Join us at GIANT this year and immerse yourself in Europe's greatest festival of healthcare innovation. Find inspiration from global leading innovators, and discover the advances in technology that are revolutionizing healthcare provision. GIANT 2021 is set to be our biggest event yet so don't miss out. GIANT Health event is an invaluable, cost-effective global hybrid event. Combining both a real-world physical trade show and multiple conferences in central London, as well as a sophisticated and engaging virtual event based on GIANT Health’s proprietary Virtual Event Platform. Learn more about Digital Therapeutics. Would you like to network with 1000s and 1000s of Europe's leading healthcare and technology innovators, hospital leaders, health-sector investors, and entrepreneurs? Over 400 speakers will convene in 15+ conference at the massive GIANT Health Event, 30 November - 1 December, 2021. Come join us in person or remotely. Early Bird tickets are now available. CLAIM YOUR TICKET HERE A special promotional code which allows to save up to 25% on top is available for our subscribers: MEDIA25 See you there! Media contact: GIANT Health Events Ltd Olga Nosova +44 20 8144 9779 Olga@GIANT.health

Read More

HEALTH TECHNOLOGY

PulsePoint Releases Next Generation Health Media Platform With Advanced Automation And AI

PulsePoint | July 06, 2021

PulsePoint, a technology company revolutionizing health decision-making in real-time, today announced the next generation launch of its digital media buying platform, Life by PulsePoint™. Its enhanced AI and automation simplifies and supercharges the media planning, activation, and optimization processes. Designed for the self-serve programmatic trader, these updates promote efficiencies and surface predictive and in-flight campaign analytics for quick strategic decisioning to yield higher media return on investment. Built upon PulsePoint's extensive data foundation, Genome™, that proactively uses microdata to capture attention when intent is signaled, Life is the leading healthcare end-to-end programmatic platform. Life's automated machine learning and AI allows marketers to quickly create highly-customized segments that classify populations in real-time, and deliver sequential messaging to drive customer actions in the moment and across the health journey. This next generation of the Life platform includes: • Advanced media planning innovations: Life offers an AI-powered forecasting tool used to run simulations to generate predictive performance metrics and intelligent audience insights. This makes it easier for marketers to preview budgets and ideate and adjust tactics to obtain their desired campaign outcomes, all before a single dollar is spent. Each forecast is powered by detailed supply and channel insights, like expected delivery, and campaign performance can be viewed by a variety of dimensions, including creative types, domains/apps, condition categories, healthcare professional specialties, geographies, among others. • Better campaign management with advanced dashboard: An automated and real-time view of line item performance and pacing gives traders a deeper, more granular look into their campaigns, making it easier for them to optimize their spend based on flight delivery and anticipate new incremental opportunities. The dashboard not only surfaces key numbers, but it also includes dynamic performance charts to uncover real-time campaign insights. • Turnkey PMP (private marketplaces) deal builder: Enhanced with turnkey end-to-end functionality, self-serve traders can now enable the deals that they negotiated directly with publishers and/or SSPs through Life's UI, decreasing the time it takes to launch PMPs. "Life was built for the healthcare marketer to simplify and optimize marketing campaigns," said Andrew Stark, CRO of PulsePoint. "Our newest capabilities increase efficiencies through advanced forecasting and real-time performance optimization, enabling more control and enhanced campaign management." Life by PulsePoint provides access to over 110 billion daily impressions across more than 2 million health pages, reaching 1.8M+ opted-in, verified healthcare professionals and over 90% of the online U.S. population. This release is just another step in PulsePoint's journey to deliver personalized messaging at each stage of the health journey using predictive insights built on real-time data. The company was recently acquired by Internet Brands, a KKR portfolio company and owner of WebMD Health Corp. PulsePoint's teams will continue to operate as their own division from their existing hubs in New York, San Francisco, and London. About PulsePoint PulsePoint is a leading technology company that uses real-world data in real-time to optimize campaign performance and revolutionize health decision-making. Leveraging proprietary datasets and methodology, PulsePoint targets healthcare professionals and patients with an unprecedented level of accuracy—delivering unparalleled results to the clients we serve.

Read More

HEALTH TECHNOLOGY

Future Health announced today that it has completely digitalised its annual in-person event at ExCeL London

Future Health | March 02, 2021

Future Health has completely rebranded during lockdown, and the flagship face-to-face event Future Health Innovations at ExCeL is now complemented by a global virtual conference series, under the brand UK Health Week. Free for delegates to attend, it is CPD and CME accredited. Participants will be able to connect, meet buyers and partake in cross border purchasing, education and deal making, enabling an increased ROI and profitable encounters with its AI powered networking software. Further Health Weeks are being rolled out around the world over the course of the coming months, and will be territory specific. Dawn Barclay-Ross, Event Director commented: “I think there will always be a place for face-to-face events; and we are contracted with ExCeL for a live ‘in person’ event four years in advance to 2025. However, as a result of international travel restrictions, health professionals in global markets are looking for on-line engagement”. Future Health offers buyers and sellers the ability to operate on line, and to research and access the products and services that their hospitals and citizens desperately need. Dawn concluded, “In the immediate post COVID era, health buyers want to be able to operate from the comfort of their desk or smart device, and they now can, from literally anywhere in the world”. AboutFuture Health Future Health is an independent exhibition and conference organiser, based in London in the UK. For further information regarding exhibiting, visiting and sponsorship opportunities at Future Health Innovations or UK Health Week Please call +44 (0) 208 012 8511 Email: hello@futurehealthinnovations.com or to sign up to the Future Health platform, register at www.futurehealthinnovations.com

Read More

HEALTH TECHNOLOGY

L2Mtech GmbH Receives CE Mark Approval on 6(SIX) products for Cardiovascular and Endovascular Applications

L2Mtech | February 17, 2021

CE Mark Approval for LimusTrack™, Sirolimus Eluting Coronary Stent System for Cardiovascular Applications. CE Mark Approval for LomiFlow™, Paclitaxel Drug Eluting Balloon for Cardiovascular Applications CE Mark Approval for PearlFlow™, Paclitaxel Drug Elutin Balloon for Endovascular Applications CE Mark Approval for PearlFlow NS™, Self Expandable Nitinol Stent System for Endovascular Applications CE Mark Approval for FlexiTrack 018™, Peripheral Balloon Catheter for Endovascular Applications CE Mark Approval for FlexiTrack 035™, Peripheral Balloon Catheter for Endovascular Applications Bonn, Germany – L2Mtech GmbH has announced the award of its first CE Mark approval on Six (6) products: LimusTrack™ : Sirolimus Coated Cobalt Chromium Stent with biodegradable polymer for the treatment of coronary artery disease, de novo lesions, restenosis lesions. LomiFlow™ : Paclitaxel Coated balloon catheter for the treatment of coronary artery disease, small vessels, dilatation of de novo lesions, in-stent restenosis (ISR) cases. PearlFlow™ : Paclitaxel Coated balloon catheter for the treatment of peripheral arterial disease, PTA, dilatation of stenotic segments or lesions in peripheral arteries. PearlFlow NS™ : Self-Expanding Nitinol Stent System for the treatment of peripheral arterial disease, de novo lesions, lesions in femoropopliteal arteries. FlexiTrack 018™ : Peripheral Balloon Dilatation catheter for the treatment of peripheral arterial disease, dilatation of lesions in femoral, popliteal, tibial arteries. FlexiTrack 035™ : Peripheral Balloon Dilatation catheter for the treatment of peripheral arterial disease, dilatation of lesions in the SFA, femoral arteries. L2Mtech GmbH Founder and CEO Lalit Mamtani said ‘‘We are very excited to have been awarded our first CE Mark on six products, CE Mark approval represents a key milestone for L2Mtech GmbH and is a testament to the efficacy and safety of our innovative technology products for Cardiovascular and Endovascular applications.“ We now prepare to commercially launch the products in all markets where the CE Mark is recognized. With introduction of our innovative technology products in markets, we will be able to expand treatment options for the benefit of many millions of patients with coronary and peripheral artery disease around the world. About L2Mtech Founded in 2017, L2Mtech GmbH is a privately-owned multinational medical device company headquartered at Bonn, Germany. L2Mtech specializes in design, development, manufacture and commercialization of medical devices that are used by healthcare establishments globally. L2MTech will provide interventional physicians with innovative vascular devices including Drug Eluting Balloon manufactured in Europe.Our Core mission is to build a product portfolio focused on minimally invasive treatment for patients with cardiovascular,endovascular and vascular artery disease. For further information, please visit : L2MTech.de Media Contact: L2Mtech GmbH admin@L2Mtech.de +49 228 94730761

Read More

Spotlight

Full Story: http://bit.ly/1PZ7dMw - An innovative new tool in the fight against breast cancer allows patients to undergo a one-time radiation treatment, directly in the cavity where the tumor has been removed, during surgery for early-stage breast cancer. A team of community and faculty doctors at Emory University Hospital Midtown is now treating patients with Intraoperative Radiation Therapy (IORT) during breast-conserving surgeries.

Resources